Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), will launch Strangvac® in Finland and vaccine vials are expected to be available for delivery shortly. ... Read more
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 14 May 2025 at 3.00 p.m. at Cirio Advokatbyrå, ... Read more
Intervacc AB (publ) announces that the company's 2024 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on ... Read more
Intervacc AB (publ) today announces that the variation application previously submitted to the U.K’s Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes ... Read more
Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the recently completed rights issue. The members of the Nomination Committee have been ... Read more
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH ... Read more